Cardiovascular Safety Evaluation of Febuxostat and Allopurinol: Findings from the FDA Adverse Event Reporting System

Cardiovascular Safety Evaluation of Febuxostat and Allopurinol: Findings from the FDA Adverse Event Reporting System

Background: Febuxostat and allopurinol are the most commonly used uric acid-lowering medications, and their safety is of great concern, especially the cardiovascular adverse reactions associated with febuxostat. We propose to study the cardiovascular toxicity of febuxostat and allopurinol using the...

Full description

Bibliographic Details
Main Authors: Yang Bai, Bin Wu, Liangwen Gou, Zhenwei Fang, Ting Xu, Tiejun Zhang, Yuwen Li
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Journal of Clinical Medicine
Subjects:
febuxostat
allopurinol
FAERS
cardiovascular toxicity
adverse event
Online Access:https://www.mdpi.com/2077-0383/12/18/6089

Internet

https://www.mdpi.com/2077-0383/12/18/6089

Similar Items